Abstract: Embodiments herein relate to implantable systems and methods for treatment of pancreatic cancer. In an embodiment, a method of treating pancreatic cancer is included, the method including inserting an electrical stimulation lead through the inferior vena cava, a hepatic vein, and into the portal vein via a transjugular intrahepatic portosystem shunt (TIPS). The method can further include inserting the electrical stimulation lead into at least one of the superior mesenteric vein and the splenic vein. The method can further include positioning electrodes on the lead within at least one of the superior mesenteric vein and the splenic vein and delivering one or more electric fields through the electrodes to a treatment zone including at least a portion of the pancreas. The electric fields can be at frequencies and a field strength effective to prevent and/or disrupt cellular mitosis in a cell.

Abstract: Delivery devices, systems, and methods for delivering implantable leadless pacing devices are disclosed. An example delivery device may include a proximal section including a deflection mechanism for deflecting the proximal section, and a distal holding section extending distally of a distal end of the proximal section and defining a cavity therein for receiving an implantable leadless pacing device. The distal holding section may be structured to have portions that flex and bend while allowing the implantable device to be recaptured within the distal holding section.

Abstract: Embodiments herein relate to implantable systems for cancer treatment and related methods. In an embodiment, an implantable system for cancer treatment is included having a therapy output circuit configured to generate an electrical current for a plurality of electric field therapy electrodes to create one or more electric fields and control circuitry that causes the therapy output circuit to generate the one or more electric fields at frequencies selected from a range of between 10 kHz to 1 MHz within a bodily tissue. The control circuitry can be configured to select between operating in a first mode or a second mode of generating the electrical current for the electric field therapy electrodes based on a minimum electrical field strength threshold, wherein the first mode includes modulating amplitude of the electrical current and the second mode includes duty cycling of the electrical current. Other embodiments are also included herein.

Abstract: Embodiments herein relate to implantable systems for cancer treatment and related methods. In an embodiment, an implantable system for cancer treatment is included having a plurality of implantable stimulation leads, a plurality of electric field therapy electrodes, a therapy output circuit, and control circuitry. The therapy output circuit can generate an electrical current for the plurality of electric field therapy electrodes to create one or more electric fields that are effective to prevent and/or disrupt cellular mitosis in a cell. The control circuitry can be configured to cause the electrical current to be distributed asymmetrically between working electrodes and counter electrodes amongst the plurality of electric field therapy electrodes. At least some of the plurality of electric field therapy electrodes are disposed on the plurality of implantable stimulation leads and in electrical communication with the therapy output circuit. Other embodiments are also included herein.

Abstract: The present invention provides novel rapidly growing microorganisms and methods for their use in cloning or subcloning nucleic acid molecules. The rapid growing microorganisms of the present invention form colonies more rapidly than microorganisms typically used in molecular biology and thus provide a significant improvement in in vitro cloning methods used extensively in molecular biology. The invention also relates to kits and compositions used in the methods of the invention.

Abstract: The present invention provides novel rapidly growing microorganisms and methods for their use in cloning or subcloning nucleic acid molecules. The rapid growing microorganisms of the present invention form colonies more rapidly than microorganisms typically used in molecular biology and thus provide a significant improvement in in vitro cloning methods used extensively in molecular biology. The invention also relates to kits and compositions used in the methods of the invention.

Abstract: The present invention provides novel rapidly growing microorganisms and methods for their use in cloning or subcloning nucleic acid molecules. The rapid growing microorganisms of the present invention form colonies more rapidly than microorganisms typically used in molecular biology and thus provide a significant improvement in in vitro cloning methods used extensively in molecular biology. The invention also relates to kits and compositions used in the methods of the invention.

Abstract: The present invention provides novel rapidly growing microorganisms and methods for their use in cloning or subcloning nucleic acid molecules. The rapid growing microorganisms of the present invention form colonies more rapidly than microorganisms typically used in molecular biology and thus provide a significant improvement in in vitro cloning methods used extensively in molecular biology. The invention also relates to kits and compositions used in the methods of the invention.

Abstract: The present invention provides novel rapidly growing microorganisms and methods for their use in cloning or subcloning nucleic acid molecules. The rapid growing microorganisms of the present invention form colonies more rapidly than microorganisms typically used in molecular biology and thus provide a significant improvement in in vitro cloning methods used extensively in molecular biology. The invention also relates to kits and compositions used in the methods of the invention.

Abstract: The present invention is directed to recombinant hosts which contain and express the AluI Type-II restriction endonuclease gene. The present invention is also directed to vectors or DNA molecules which contain the gene, and to methods of producing the AluI enzyme. One source of the enzyme is Arthrobacter luteus, although other microorganisms may be used to isolate restriction endonuclease isoschizomers of the invention.

Abstract: The invention relates to a substantially pure thermostable DNA polymerase. Preferably, the DNA polymerase has a molecular weight of about 95 kilodaltons and is more thermostable than Taq DNA polymerase. The present invention also relates to cloning and expression of the DNA polymerase in E. coli, to DNA molecules containing the cloned gene, and to host cells which express said genes.